search
Back to results

Neurologic Signatures of Chronic Pain Disorders

Primary Purpose

Chronic Pain, Chronic Migraine, Fibromyalgia

Status
Completed
Phase
Phase 4
Locations
Taiwan
Study Type
Interventional
Intervention
flunarizine and/or pregabalin
Sponsored by
Taipei Veterans General Hospital, Taiwan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Chronic Pain

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Control: devoid of any systemic or neurological diseases
  • Chronic migraine: by ICHD-III (International Classification of Headache Disorder) criteria
  • Fibromyalgia: by ACR (American College of Rheumatology) 2010 criteria

Exclusion Criteria:

  • history of major systemic illness, including uncontrolled hypertension, diabetes, chronic renal insufficiency, autoimmune diseases or malignancies
  • history of neurological disorders which might affect sensation such as previous stroke or peripheral neuropathy
  • history of substance abuse (except painkillers)
  • heavy smokers (with a daily consumption >20 cigarettes)
  • pregnancy or lactation
  • any contraindication for magnetic resonance imaging (MRI)
  • and any obvious infection or inflammation over a period of at least 1 month before the study.

Sites / Locations

  • Headache Center, Teipei Veterans General Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

patients with chronic migraine

patients with fibromyalgia

patients with chronic migraine and fibromyalgia

Arm Description

flunarizine for patients with chronic migraine

pregabalin for patients with fibromyalgia

flunarizine and pregabalin for patients with chronic migraine and myalgia

Outcomes

Primary Outcome Measures

clinical improvement after treatment (1) headache/pain intensity [NRS, numeric rating scale]
clinical improvement (headache/pain intensity) after treatment unit: NRS (numeric rating scale, 0-10) analysis: comparing the mean headache/pain intensity in each month after treatment (M1/M2/M3/M4) to that before treatment (M-1)
clinical improvement after treatment (2) headache/pain frequency [attacks per month]
clinical improvement (headache/pain frequency) after treatment unit: attacks per month analysis: comparing the mean headache/pain frequency in each month after treatment (M1/M2/M3/M4) to that before treatment (M-1)
clinical improvement after treatment (3) headache/pain duration [hours per day]
clinical improvement (headache/pain duration) after treatment unit: hours/day analysis: comparing the mean headache/pain duration (hours/day) in each month after treatment (M1/M2/M3/M4) to that before treatment (M-1)

Secondary Outcome Measures

EEG change after treatment
Linear and nonlinear analysis of EEG before and after treatment Three EEG session will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 2-month/4-month treatment course, respectively. The EEG analyses include linear (eg: power spectrum, coherence, functional connectivity) analyses as well as non-linear (eg: entropy) analyses.
sensory and pain threshold change after treatment
Using quantitative sensory testing (QST) to evaluate the sensory and pain threshold before and after treatment Three QST session will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 2-month/4-month treatment course, respectively. Equipment: electric von Fray filaments unit: gram
Autonomic function change after treatment
Using heart rate variability (HRV) to evaluate autonomic function before and after treatment Three HRV session will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 2-month/4-month treatment course, respectively. The HRV analyses include time-domain (eg: mean heart rate and its variation, mean R-R interval and its variation), and also frequency domain analysis (eg: power spectrum)

Full Information

First Posted
April 1, 2016
Last Updated
October 28, 2020
Sponsor
Taipei Veterans General Hospital, Taiwan
Collaborators
Ministry of Science and Technology, R.O.C.
search

1. Study Identification

Unique Protocol Identification Number
NCT02747940
Brief Title
Neurologic Signatures of Chronic Pain Disorders
Official Title
Neurologic Signatures of Chronic Pain Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
December 2015 (undefined)
Primary Completion Date
December 2019 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taipei Veterans General Hospital, Taiwan
Collaborators
Ministry of Science and Technology, R.O.C.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
"Brain signatures" as objective measures of acute pain have been characterized with functional magnetic resonance image and machine learning technology. As compared to acute pain, chronic pain leads to greater socioeconomic burden. However, measures for chronic pain remain subjective and suboptimal, and the brain signatures for chronic pain are largely unknown. Chronic migraine and fibromyalgia are two prototypes primary chronic pain disorders with high disability and intractability with prevalence of around 2% for both diseases. These two chronic pain disorders have shared clinical presentations (abnormal pain sensitivity, mood and sleep disorders), pathophysiology (central sensitization) and medical treatment (anti-depressants), despite different body parts are involved (head vs. whole body). The present integrated project aims to characterize both common and disease-specific brain signatures of chronic pain by investigating these two chronic pain disorders. Our findings may shed some light on the key mechanisms of pain chronification, and may pave the way for the optimization of diagnosis and prognostication, as well as formulation of personalized medicine in chronic pain, so as to improve life quality of these patients and to reduce socioeconomic loss. The present project includes three interdisciplinary sub-projects (plus one animal study, not listed here): A: Clinical studies for chronic migraine and fibromyalgia: endophenotypes and pain chronification B: Functional neuroimaging of chronic pain: multimodal quantitative analysis of brain connectomes C. Data stream mining technology for multimodal physiological signals of chronic pain: real-time tracking and clinical correlation The specific aims of the present projects include: Identification of common and disease-specific brain signatures for chronic pain (sub-projects A, B, C) Investigation of clinical indicators with predictive values by machine learning analysis of big data (sub-projects A, B, C) Elucidation of the specific anatomical structures or neural networks underpinning pain chronification based on clinical neuroimaging (sub-projects A, B) In this 1st-year pilot study of the 4-year longitudinal study, we will establish experimental platforms for each sub-project, start to recruit participants and perform endophenotyping, as well as have a preliminary integration for sub-projects A, B and C.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Pain, Chronic Migraine, Fibromyalgia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
patients with chronic migraine
Arm Type
Experimental
Arm Description
flunarizine for patients with chronic migraine
Arm Title
patients with fibromyalgia
Arm Type
Experimental
Arm Description
pregabalin for patients with fibromyalgia
Arm Title
patients with chronic migraine and fibromyalgia
Arm Type
Experimental
Arm Description
flunarizine and pregabalin for patients with chronic migraine and myalgia
Intervention Type
Drug
Intervention Name(s)
flunarizine and/or pregabalin
Primary Outcome Measure Information:
Title
clinical improvement after treatment (1) headache/pain intensity [NRS, numeric rating scale]
Description
clinical improvement (headache/pain intensity) after treatment unit: NRS (numeric rating scale, 0-10) analysis: comparing the mean headache/pain intensity in each month after treatment (M1/M2/M3/M4) to that before treatment (M-1)
Time Frame
4 months
Title
clinical improvement after treatment (2) headache/pain frequency [attacks per month]
Description
clinical improvement (headache/pain frequency) after treatment unit: attacks per month analysis: comparing the mean headache/pain frequency in each month after treatment (M1/M2/M3/M4) to that before treatment (M-1)
Time Frame
4 months
Title
clinical improvement after treatment (3) headache/pain duration [hours per day]
Description
clinical improvement (headache/pain duration) after treatment unit: hours/day analysis: comparing the mean headache/pain duration (hours/day) in each month after treatment (M1/M2/M3/M4) to that before treatment (M-1)
Time Frame
4 months
Secondary Outcome Measure Information:
Title
EEG change after treatment
Description
Linear and nonlinear analysis of EEG before and after treatment Three EEG session will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 2-month/4-month treatment course, respectively. The EEG analyses include linear (eg: power spectrum, coherence, functional connectivity) analyses as well as non-linear (eg: entropy) analyses.
Time Frame
4 months
Title
sensory and pain threshold change after treatment
Description
Using quantitative sensory testing (QST) to evaluate the sensory and pain threshold before and after treatment Three QST session will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 2-month/4-month treatment course, respectively. Equipment: electric von Fray filaments unit: gram
Time Frame
2 months
Title
Autonomic function change after treatment
Description
Using heart rate variability (HRV) to evaluate autonomic function before and after treatment Three HRV session will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 2-month/4-month treatment course, respectively. The HRV analyses include time-domain (eg: mean heart rate and its variation, mean R-R interval and its variation), and also frequency domain analysis (eg: power spectrum)
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Control: devoid of any systemic or neurological diseases Chronic migraine: by ICHD-III (International Classification of Headache Disorder) criteria Fibromyalgia: by ACR (American College of Rheumatology) 2010 criteria Exclusion Criteria: history of major systemic illness, including uncontrolled hypertension, diabetes, chronic renal insufficiency, autoimmune diseases or malignancies history of neurological disorders which might affect sensation such as previous stroke or peripheral neuropathy history of substance abuse (except painkillers) heavy smokers (with a daily consumption >20 cigarettes) pregnancy or lactation any contraindication for magnetic resonance imaging (MRI) and any obvious infection or inflammation over a period of at least 1 month before the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shuu-Jiun Wang, M.D.
Organizational Affiliation
Neurological Institute, Taipei Veterans General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Headache Center, Teipei Veterans General Hospital
City
Taipei
ZIP/Postal Code
112
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35708466
Citation
Pan LH, Chen WT, Wang YF, Chen SP, Lai KL, Liu HY, Hsiao FJ, Wang SJ. Resting-state occipital alpha power is associated with treatment outcome in patients with chronic migraine. Pain. 2022 Jul 1;163(7):1324-1334. doi: 10.1097/j.pain.0000000000002516. Epub 2021 Oct 13.
Results Reference
derived
PubMed Identifier
35400174
Citation
Pan LH, Wang YF, Ling YH, Lai KL, Chen SP, Chen WT, Treede RD, Wang SJ. Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study. Cephalalgia. 2022 Aug;42(9):899-909. doi: 10.1177/03331024221080572. Epub 2022 Apr 11.
Results Reference
derived
PubMed Identifier
34534180
Citation
Hsiao FJ, Chen WT, Liu HY, Wang YF, Chen SP, Lai KL, Hope Pan LL, Coppola G, Wang SJ. Migraine chronification is associated with beta-band connectivity within the pain-related cortical regions: a magnetoencephalographic study. Pain. 2021 Oct 1;162(10):2590-2598. doi: 10.1097/j.pain.0000000000002255.
Results Reference
derived
PubMed Identifier
33090368
Citation
Hsiao FJ, Chen WT, Ko YC, Liu HY, Wang YF, Chen SP, Lai KL, Lin HY, Coppola G, Wang SJ. Neuromagnetic Amygdala Response to Pain-Related Fear as a Brain Signature of Fibromyalgia. Pain Ther. 2020 Dec;9(2):765-781. doi: 10.1007/s40122-020-00206-z. Epub 2020 Oct 22.
Results Reference
derived

Learn more about this trial

Neurologic Signatures of Chronic Pain Disorders

We'll reach out to this number within 24 hrs